Avadel CNS Pharmaceuticals, LLC is a Delaware limited liability company and a wholly owned subsidiary of Avadel US Holdings, Inc., which is in turn wholly owned by Avadel Pharmaceuticals plc (Nasdaq: AVDL), an Irish public limited company. Its U.S. principal place of business is 16640 Chesterfield Grove Road, Chesterfield, Missouri; the parent is headquartered in Dublin, Ireland. Avadel plc was incorporated in Ireland in December 2015 as successor to Flamel Technologies (founded 1990) and took its current name in January 2017. Per its FY2024 Form 10-K, Avadel plc reported approximately 188 employees and $169.1 million in net product revenue, with a net loss of $48.8 million; market capitalization was reported near $1.4 billion in 2024.
Avadel CNS is the entity holding and developing the company's narcolepsy franchise. Its sole commercial product is LUMRYZ (sodium oxybate), an extended-release, once-nightly formulation approved by the FDA in May 2023 for cataplexy or excessive daytime sleepiness in adults with narcolepsy, and in October 2024 for patients aged seven and older. LUMRYZ uses the parent's proprietary Micropump drug-delivery technology, is dispensed through a restricted REMS distribution program, and is sold to specialty pharmacies. The parent previously marketed hospital injectables but has since refocused on sleep medicine. This is an operating company, not a patent assertion entity.
Litigation posture: Avadel CNS is an active two-way litigant — 9 tracked plaintiff cases and 9 defendant cases — dominated by Hatch-Waxman/Orange Book disputes rather than NPE-style assertion. Venues are the District of Delaware, the District of Columbia, the District of New Jersey, and the Federal Circuit; no Eastern District of Texas filings appear in the tracked data.
Notable matters: Jazz Pharmaceuticals sued Avadel CNS repeatedly (2021–2022) over sodium oxybate patents, including a REMS-distribution patent later delisted from the Orange Book; a February 2024 Delaware jury awarded Jazz roughly $233,562.83 on one process patent. Avadel CNS counterclaimed with Sherman Act claims over the Orange Book listing and filed its own infringement suits against Jazz in 2023 and 2025. Avadel also sued HHS Secretary Becerra in D.D.C. (2022) over its FDA application, and in July 2026 filed against Granules India Limited in New Jersey. The parties announced a global settlement in October 2025.